Sunday, December 31, 2017

Happy New Year From Integrated BioSci Investing

Summary

  • We wish all readers, partners, and friends as well as our community of experts, including physicians, scientists, fund managers, investment advisors, market leaders, and everyday investors a Happy New Year.
  • May 2018 brings you and your family much health, wealth, and joy.
  • If you have yet to sign up with Integrated BioSci Investing, now is a good time to lock in the legacy price as we're raising our price in early 2018.

Every time you tear a leaf off a calendar, you present a new place for new ideas and progress - Charles Kettering

We’re honored that you took the time out of your holiday to read our market intelligence. If 2017 did not bring you much luck, perhaps you can increase your luck in 2018 by conducting more due diligence and/or partnering up with our marketplace. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions.

To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 210% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 180% gains; Kite Pharma netted 82%. Exelixis Inc (NASDAQ:EXEL) earned greater than 50% capital appreciation. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Figure 1: 2017 notable Integrated BioSci performers. (Source: Google Finance).

On the behalf of IBI, we sincerely wish all readers and friends, as well as our community of experts, including physicians, scientists, fund managers, investment advisors, market leaders, and everyday investors a Happy New Year. May fiscal 2018 brings you much wealth, health, and joy!

Figure 2: Integrated BioSci Investing greeting. (Source: Dr. Tran BioSci)

Notably, we’ll increase our price soon. SUBSCRIBE TO OUR MARKETPLACE RESEARCH NOW TO LOCK IN the legacy price and save money in the future. To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK THE ORANGE FOLLOW BUTTON. Lastly, you can read up on Dr. Tran’s background by following this link.

Wednesday, December 27, 2017

Integrated BioSci Report Of Alpha-Intelligence On Spark Therapeutics: Elucidating The Ramifications Of The Approved Gene Therapy Luxturna

Summary

  • First FDA-approved gene therapy, Luxturna, for the treatment of a rare eye disease will be available within months. Unprecedented approval set the tone for further acceptance of similar gene therapies in the foreseeable future.
  • Orphan designation enabled the company to charge a premium pricing to offset the lengthy and low success innovation process.
  • With proof that their stellar technology works, Spark is most likely a prime target of acquisition.
  • Rare Pediatric Disease Priority Review (“RPDPR”) voucher earned can be used for subsequent marketing application or sell to another firm for roughly $60M.
  • It’s prudent to build shares while the market has yet to recognize the substantial unlocked value in this firm.

“Finding the really outstanding companies and staying with them through all the fluctuations of a gyrating market proved far more profitable to far more people than did the more colorful practice of trying to buy them cheap and sell them dear.” - Philip Fisher

On Dec. 19, 2017, Spark Therapeutics (NASDAQ:ONCE), a leading gene therapy innovator, announced that the US FDA approved voretigene neparvovec-rzyl (Luxturna) - a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy. Interestingly, the market has been ambivalent regarding this news due to the lackluster data presentation at the 59th annual meeting of American Society of Hematology (“ASH”). Despite the monumental news, the price only traded up by $2.55 at $52.75 (for 5.08% profits). Thereafter, the share price traded North only at $54.06, which is quite meager based on its substantial unlocked value.

Figure 1: Spark Therapeutics stock chart. (Source: StockCharts).

At Integrated BioSci Investing, we have much success in finding robust performers. For instance, Nektar Therapeutics (NASDAQ:NKTR) appreciated over 210% for subscribers. In this report, we'll elucidate the ramifications of the Luxturna approval and to assess Spark Therapeutics’ prospects as a potential big winner for 2018.

Author Note: We're honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics procured more than 210% profits while Spectrum Pharmaceuticals (SPPI) delivered over 180% gains. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. This article is the introductory preview version of the weekly Alpha-Intelligence Integrated BioSci research that we published in advance to IBI subscribers.
Notably, we'll increase prices soon. Subscribe to our Marketplace research now to lock in the legacy price and save money in the future.To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and click on the orange "Follow" button. Further, you can read up on Dr. Tran’s background by following this link.

Monday, December 25, 2017

Integrated BioSci Investing: A Season Greeting From Dr. Tran BioSci

Summary

  • We're what we are today due to the support of our community of expert readers, who are physicians, scientists, market leaders, fund managers, analysts, executives, and everyday investors.
  • We're greatly appreciative of your stock tips, advice, wisdom, partnership, and friendship.
  • We're continuing to learn and to grow. Merry Christmas and a Happy Holiday to you all.

We've grown much over the years (especially this year) as we’re blessed with a growing community of expert readers, who we view as teachers, business partners, and friends. Despite that we deliver the analytical research and consulting to you, we also learn significantly from your insight, wisdom, and suggestions in the process. Many of our followers are highly accomplished professionals, including physicians, scientists, professors, hedge fund managers, analysts, and executives, as well as other market leaders. We owe you our gratitude, especially Mr. Jacky Xiao, CEO Abelardo Fraga, Drs. Thomas Valdez and Zach Hartman, as well as many others. Much appreciation for teaching us and growing with us as partners.
Figure 1: Dr. Tran BioSci Logo. (Source: Dr. Tran BioSci of Integrated BioSci Investing).
It has been a blessing, as we've made mostly winning calls that greatly benefitted our community. Nektar Therapeutics (NASDAQ:NKTR) appreciated over 210%, Spectrum Pharmaceuticals (NASDAQ:SPPI) delivers over 170% profits, Kite Pharma (NASDAQ:KITE) procured over 82%, Exelixis (NASDAQ:EXEL) banked in over 50%, just to name a few. Our expert interviewing guests, including Biotech Beast, Decision Analytics, and Terry Chrisomalis made stellar calls that profited our readers substantially. And, we are greatly appreciative of their wisdom.
We’re also thankful for Seeking Alpha, Seeking Alpha editors, Robyn Conti, and Daniel Shvartsman for their ongoing guidance and support. In addition, we wish to send our gratitude to Richard Berger, who had advised us on how to grow our marketplace ("MP"). We recommend that you join his MP, Engineered Income Investing. The former executive is wise and has a strong track record of performance.
Figure 2: Notable BioSci Performers. (Source: Google Finance)
Of note, there are many companies we’re featuring in our MP that are highly likely to appreciate substantially in 2018 and for years to come. If you have yet to sign up with Integrate BioSci Investing, right now is a good time to do so to lock in the legacy price (as we're raising the price soon). And, we're implementing stellar developments. Much excitement to come.
On the behalf of Integrated BioSci Investing, we wish you and your family a Merry Christmas and a Happy Holiday. May this season fill you with joy.
Figure 3: Christmas Greeting. (Source: Christmas WallPaper)
Author Note: We're honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics procured more than 210% profits while Spectrum Pharmaceuticals (SPPI) delivered over 180% gains. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.
Notably, we'll increase prices soon. Subscribe to our Marketplace research now to lock in the legacy price and save money in the future.To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and click on the orange "Follow" button. Besides the exclusives, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by following this link.

Tuesday, November 28, 2017

An Integrated BioSci Research On Crispr Therapeutics: The Future Of Individualized Medicine

Summary

  • CRISPR is the revolutionary method of genes editing that can potentially treat a vast number of genetic diseases.
  • The company is also brewing its own line of promising CAR-Ts.
  • The partnership with Vertex to access its extensive resources. Fifty percent ownership of Casebia Therapeutics with Bayer to broaden the firm’s pipeline.
  • Abundant cash to fund development for the next two years.
  • This is the exclusive article for subscribers that we decided to publish earlier this week.


Since Oct. 28, 2016, shares of Crispr Therapeutics (NASDAQ:CRSP), a bioscience firm, focusing on the development and commercialization of gene editing and CAR-T to treat cancers and genetic diseases increased by $5.61 to trade at $19.48 for  (over 40% profits). Of note, the recent FDA approval of the two CAR-T products - tisagenlecleucel (Kymriah) of Novartis (NYSE:NVS) for the treatment of refractory acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta) of Gilead (NASDAQ:GILD) for resistant non-Hodgkin lymphomas - opened doors to similar therapeutics. With such exciting developments, Crispr’s share price would have been trading at much higher valuation without the patent litigation issue. In this report, we’ll explicate the company’s stellar technology (gene editing and CAR-T) while going over the patent concern, the robust financials as well as the superb management.


Figure 1: Crispr stock chart. (Source: StockCharts)

Author’s Notes: The full Integrated BioSci Research is available to subscribers of our marketplace service, Integrated BioSci Investing(where we also deliver in-depth consulting and key market-moving catalyst events).